Lutetium-177 zadavotide guraxetan

N/A

Report date: 2026/03/19 10:12:36

NME

Base Information

Drug NameLutetium-177 zadavotide guraxetan

Drug Alias Name177-Lutetium-PSMA-I&T (Curium)177Lu-PSMA-I&T (Curium)177LU-PSMA-I&T (Curium)Lu-177-PSMA-I&T (Curium)Lutetium (177Lu) zadavotide guraxetan (Curium) +[7]

ClassificationSmall molecules > Synthetic peptide > Peptide drug conjugate (PDC)Radiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Radionuclide Drug Conjugates +[4]

Mechanisms of ActionProstate-Specific Membrane Antigen inhibitorsPositron-emission tomography enhancersIonising radiation emitters

TargetsProstate-Specific Membrane Antigen

Therapy Area/IndicationsProstatic Neoplasms, Castration-ResistantProstatic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesItalyFrance +[5]

CombinationsNo

Global Highest StatusPhase 3 Clinical

Highest Status in ChinaPhase 1 Clinical

Originator CompaniesCurium Us Llc

China Registration ClassN/A

Develop Information

Active CompaniesCurium Us Llc

Inactive CompaniesN/A

Active IndicationsProstatic Neoplasms, Castration-ResistantProstatic Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A